Search for a trial

Fast-track thyroidectomy and I-131 radioiodine ablation therapy in patients with differentiated thyroid cancer.

Firstly, to study the reduction in sick-leave time achieved by the treatment protocol. Secondly to study the quality of life in the patients treated in the fast-track protocol, to study the reduction in societal costs and to stdy the efficacy of a…

The influence of metformin and a hypocaloric diet on thyroid radioactive iodide uptake in healthy volunteers: a pilot study.

To assess the physiological effects of metformin and hypocaloric dieting on thyroid iodide uptake and thyroid function in healthy volunteers.

Randomized phase II study of BEZ235 or everolimus in advanced pancreatic neuroendocrine tumors

To assess the treatment effect of BEZ235 relative to everolimus on progression free survival in patients with advanced pancreatic neuroendocrine tumors who have not been previously treated with an mTOR inhibitor.

Fast-track thyroidectomy and radioiodine ablation therapy in patients with differentiated thyroid cancer.

This study aims to detect differences in sick leave time, associated costs and quality of life between differentiated thyroid cancer patients treated in either a fast-track protocol or a traditional longer time interval between total thyroidectomy…

Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymus -LUNA Trial

To evaluate the efficacy of pasireotide LAR and everolimus alone or in combination in progressive patients with a well differentiated neuroendocrine tumor of the lung or thymus.

A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients with Pancreatic Cancer

The primary objective of the Phase 2 part of the study is to determine if overall survival(OS) in patients with Stage II-IV unresectable pancreatic cancer administered LY2603618 and gemcitabine combination therapy exceeds gemcitabine monotherapy OS.…

Web-based tailored Information and support for patients with a Neuroendocrine tumor

This study aims to investigate whether a web-based tailored information and support system reduces distress, as determined by a decrease in value of the distress thermometer, and/or improves patients* perception and satisfaction of received…

De-escalation of treatment for Papillary Thyroid Cancer followed by Active Surveillance - a pilot study

Primary Objective: The aim of this pilot study is to determine the willingness of patients to participate in a RCT regarding de-escalation of treatment of PTC and to observe adherence to this less aggressive approach. This will be accomplished by…

Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

This study has been transitioned to CTIS with ID 2023-509334-19-00 check the CTIS register for the current data. This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety,…

Standard versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes after Whipple procedure (SPARROW): a multicenter, randomized controlled trial

This study has been transitioned to CTIS with ID 2024-510766-16-00 check the CTIS register for the current data. This trial evaluates the additional value of pre-emptive antibiotic treatment on clinically relevant OSIs in patients undergoing…

A Phase 3, Multicenter, Open-label, Randomized Study of nab®-Paclitaxel Plus Gemcitabine versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma

Primary Objective- The primary objective of the study is: * to compare DFS between subjects randomized to nabpaclitaxel plus gemcitabine and subjects randomized to gemcitabine alone.Secondary Objectives- The secondary objectives of the study are to…

A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with Grade 2 and Grade 3 advanced GEP-NET

This study has been transitioned to CTIS with ID 2023-507443-10-00 check the CTIS register for the current data. The pivotal Phase III NETTER-1 study showed that Lutathera with best supportive care (30mg octreotide long-acting) provided a…

A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient- reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)

This study has been transitioned to CTIS with ID 2024-510812-64-00 check the CTIS register for the current data. The purpose of this study is to investigate the efficacy and safety of the investigational drug known as Lutetium (177Lu) edotreotide in…

Phase I clinical trial using a novel CCK-2/gastrin receptor-localizing radiolabelled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma

Primary Objectives1. to establish the safety of intravenous administration of a therapeutic peptideamount of the CP042. to assess the biodistribution and dosimetry of 111In-CP04 in cancer and normal tissues and to determine critical organs.Secondary…